Related Experiment Video

Updated: Dec 7, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2

Sebastiano Bruno Solerte1,2, Francesca D'Addio3, Roberto Trevisan4

  • 1Department of Internal Medicine, Geriatric and Diabetology Unit, University of Pavia, Italy.

Diabetes Care
|September 30, 2020
PubMed

Insights

Sitagliptin treatment in hospitalized patients with type 2 diabetes and COVID-19 significantly reduced mortality and improved clinical outcomes. This suggests sitagliptin may be a beneficial therapeutic approach for this vulnerable patient population.

Area of Science:

  • Internal Medicine
  • Infectious Diseases
  • Endocrinology

Background:

  • Patients with type 2 diabetes (T2D) and coronavirus disease 2019 (COVID-19) exhibit poor outcomes.
  • Novel therapeutic strategies are crucial for managing T2D patients hospitalized with COVID-19.

Purpose of the Study:

  • To investigate the efficacy of sitagliptin as an add-on therapy for hospitalized patients with T2D and COVID-19.

Main Methods:

  • A multicenter, case-control, retrospective, observational study.
  • 169 patients with T2D and COVID-19 received sitagliptin plus standard care; 169 matched controls received standard care.
  • Primary endpoints included hospital discharge/mortality and clinical outcome improvement.

Main Results:

  • Sitagliptin use was associated with significantly reduced mortality (18% vs. 37%, P=0.0001).
  • Improved clinical outcomes were observed in 60% of sitagliptin patients versus 38% of controls (P=0.0001).
  • Higher hospital discharge rates were noted in the sitagliptin group (P=0.0008).

Conclusions:

  • Sitagliptin treatment at hospitalization was linked to better outcomes in T2D patients with COVID-19.
  • Further confirmation is warranted through ongoing randomized, placebo-controlled trials.
Abstract

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.1K
Isolation of Human Islets from Partially Pancreatectomized Patients11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

16.7K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
500
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
467
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
672
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
761